IL17A and psoriasis: In terms of IL-17 pathway inhibitors, a randomized, double-blind pilot study compared the safety and efficacy of two commercialized IL-17 inhibitors, ixekizumab and secukinumab, in the treatment of moderate-to-severe psoriasis (62).